8 hydroxy 2 dipropylamino tetralin hydrobromide 8 oh dpat

Fluoxetine (Cat# F132), (±) -8-Hydroxy-2-(dipropylamino) tetralin hydrobromide (8-OH-DPAT, Cat# H8520) and serotonin hydrochloride (5-HT, Cat# H9523) were purchased from Sigma-Aldrich (St Louis, MO, USA) and were dissolved in saline. 1-(2-Methoxyphenyl)-4-[4-(2-phthalimido) butyl] piperazine hydrobromide (NAN-190, Cat# 0553) was purchased from TOCRIS bioscience (Bristol, UK) and dissolved in saline. Betulinic acid (Cat# HY-10529) was purchased from MedChemExpress (New Jersey, USA) and dissolved in PBS. Fluoxetine (10 mg/kg/d), 8-OH-DPAT (0.1 mg/kg/d), and NAN-190 (0.3 mg/kg/d) were intraperitoneally injected for 28 days. 5-HT (10 mg/kg/d) was intraperitoneally injected for 7 days.

Resveratrol, fluoxetine, diazepam, (±)-8-Hydroxy-2-(dipropylamino) tetralin hydrobromide (8-OH-DPAT, a 5-HT_1A receptor agonist), 5-HT and 5-hydroxyindoleacetic acid (5-HIAA) were purchased from Sigma-Aldrich (St. Louis, MO, USA). NAN-190 hydrobromide (NAN-190, a 5-HT_1A receptor antagonist) was obtained from Tocris Bioscience (Ellisville, MO, USA).
All drugs were dissolved in saline and diluted to desired concentration on the day of testing except Resveratrol that was dissolved in 0.5% sodium carboxymethyl cellulose (CMC-Na). Resveratrol was administered by gavage (i.g.) at doses of 10, 20 and 40 mg/kg with a volume of 5 ml/kg body weight, 50 min before CACS procedure. fluoxetine (10 mg/kg), diazepam (1 mg/kg), 8-OH-DPAT (0.5 mg/kg) and NAN-190 hydrobromide (0.1 mg/kg) were injected intraperitoneally (i.p.) in a volume of 1 ml/kg. fluoxetine and diazepam were administered 30 min before CACS procedure. For co-administered with Resveratrol, the 5-HT_1A receptor agonist and antagonist (8-OH-DPAT and NAN-190) were injected 15 min before Resveratrol administration. All the behavioral tests started 24 h after last drug treatment (Figure 1B).